阿利西尤单抗联合瑞舒伐他汀在急性冠脉综合征患者PCI术后的应用效果  

Effects of Alirocumab combined with Rosuvastatin in the patients with acute coronary syndrome after PCI

作　　者：李亚南 LI Ya'nan(Department of Pharmacy of Pingdingshan People’s Hospital No.1,Pingdingshan 467000 Henan,China)

机构地区：[1]平顶山市第一人民医院药学部,河南平顶山467000

出　　处：《中国民康医学》2025年第8期33-36,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察阿利西尤单抗联合瑞舒伐他汀在急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后的应用效果。方法:选取2021 年10 月至2023 年10 月该院收治的96 例行PCI 术的ACS 患者进行前瞻性研究,按照随机数字表法将其分为对照组与观察组各48 例。对照组采用瑞舒伐他汀治疗,观察组在对照组基础上联合阿利西尤单抗治疗。比较两组临床疗效,治疗前后血脂指标[ 三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、心功能指标[ 左心室收缩末期内径(LVEDD)、左心室舒张末期内径(LVESD)、左心室射血分数(LVEF)] 水平,以及不良反应发生率。结果:观察组治疗总有效率为93.75%,高于对照组的79.17%,差异有统计学意义(P<0.05);治疗后,两组TG、TC、LDL-C 水平均低于治疗前,且观察组低于对照组, 差异有统计学意义(P<0.05);两组HDL-C 水平比较,差异无统计学意义(P>0.05);两组LVEDD、LVESD 水平均低于治疗前,且观察组低于对照组,两组LVEF 水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿利西尤单抗联合瑞舒伐他汀应用于ACS 患者PCI 术后可提高治疗总有效率,改善血脂指标和心功能指标水平的效果优于单纯瑞舒伐他汀治疗。Objective:To observe effects of Alirocumab combined with Rosuvastatin in the patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods:A prospective study was conducted on 96 patients with ACS after PCI admitted to the hospital from October 2021 to October 2023.According to the random number table method,they were divided into control group and observation group,48 cases in each group.The control group was treated with Rosuvastatin,while the observation group was treated with Alirocumab on the basis of that of the control group.The clinical efficacies,the levels of blood lipid indexes[triglyceride(TG),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)]and cardiac function indexes[left ventricular end-systolic diameter(LVEDD),left ventricular end-diastolic diameter(LVESD),left ventricular ejection fraction(LVEF)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.75%,which was higher than 79.17%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TG,TC and LDL-C in the two groups were lower than those before treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the HDL-C level between the two groups(P>0.05).The levels of LVEDD and LVESD in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of LVEF in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Alirocumab combined

关 键 词：急性冠脉综合征 阿利西尤单抗 瑞舒伐他汀 血脂 心功能 不良反应 

分 类 号：R972[医药卫生—药品]